Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TOCA

Tocagen (TOCA) Stock Price, News & Analysis

Tocagen logo

About Tocagen Stock (NASDAQ:TOCA)

Advanced Chart

Key Stats

Today's Range
$6.70
$7.41
50-Day Range
$1.26
$41.03
52-Week Range
$0.42
$6.77
Volume
19,309 shs
Average Volume
1.47 million shs
Market Capitalization
$170.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.

Receive TOCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tocagen and its competitors with MarketBeat's FREE daily newsletter.

TOCA Stock News Headlines

Forte Biosciences Inc (FBRX)
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
See More Headlines

TOCA Stock Analysis - Frequently Asked Questions

Tocagen Inc (NASDAQ:TOCA) released its quarterly earnings data on Thursday, April, 23rd. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. Tocagen had a negative trailing twelve-month return on equity of 327.74% and a negative net margin of 176,433.34%.

Tocagen (TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at a price of $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tocagen investors own include VBI Vaccines (VBIV), Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), T2 Biosystems (TTOO), Bristol-Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
4/23/2020
Today
4/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TOCA
Fax
N/A
Employees
77
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-63,520,000.00
Net Margins
-176,433.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Price / Cash Flow
N/A
Book Value
$0.45 per share
Price / Book
15.82

Miscellaneous

Free Float
N/A
Market Cap
$170.30 million
Optionable
Not Optionable
Beta
0.01
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:TOCA) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners